MAGEA3 and neoplasm: To discuss another avenue of tumor vaccine platform, a phase I clinical trial completed on 89 patients had profound results after conducting a period of vaccinations utilizing a liposomal RNA vaccine targeting melanoma-associated antigens NY-ESO-1, MAGE-A3, tyrosinase, and TPTE.